Summary
Flex4Pharma has a registered holding activity and consists mainly of financial fixed assets; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €30,751 and a net result of €18,711. Equity is growing by about 24% per year across the filed financial years. Its solvency ranks better than 66% of 21,956 sector peers (NACE 47, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals.
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
- AixofitFRSourceown accounts 202550%
According to the 2025 annual accounts of Flex4Pharma and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
No directors read yet: 0 of 1 Gazette act processed.